Retrospective analysis of anti-TNF therapy in inflammatory bowel diseases: a single-center retrospective study
Annals of Clinical and Analytical Medicine · 2026-11-01 · 17 (11) · 1162-1166
DOI: 10.4328/acam.50010 ↗Abstract
Aim Tumor necrosis factor (TNF) plays a pivotal role in the immunopathogenesis of inflammatory bowel disease (IBD). This study aimed to evaluate treatment response, treatment-related complications, and clinical outcomes in patients with IBD receiving anti-TNF therapy, specifically infliximab and adalimumab. Methods This retrospective study included 117 patients with IBD who received anti-TNF therapy between January 2012 and May 2017 and were followed at a unıversity gastroenterology department. Treatment responses (complete remission, partial remission, non-response, and death), treatment-related complications, and clinical outcomes were assessed using electronic medical records. Results The median age was 37.5 years (range: 20–77) in patients with Crohn’s disease and 38 years (range: 22–70) in patients with ulcerative colitis (UC). Male predominance was observed in both groups. Infliximab, adalimumab, or both agents were used in 34.0%, 51.1%, and 14.9% of UC patients, and in 45.7%, 34.3%, and 20.0% of Crohn’s disease patients, respectively. The overall response rate to anti-TNF therapy was 69.6%, with response rates of 75.0% in Crohn’s disease and 61.7% in UC. No significant differences were observed between infliximab and adalimumab or between monotherapy and combination therapy. Conclusion Anti-TNF therapy was effective and well-tolerated in both Crohn’s disease and ulcerative colitis. Treatment response was independent of demographic and disease-related factors, while secondary non-response was more common than primary non-response.
EUVIMED